$ACONW News

Last published 2w ago

2w agoACON ACONWAclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar DiscsGlobeNewswireStudy conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared
3w agoACON ACONWAclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026GlobeNewswire85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable
4w agoACON ACONWAclarion to Present at the 20th Annual LD Micro Main EventGlobeNewswireBROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ:ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset
2mo agoACON ACONWAclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial SiteGlobeNewswireUniversity of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and
3mo agoACON ACONWAclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan ProcessGlobeNewswirePatent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver more reproducible
3mo agoACON ACONWAclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the TechnologyGlobeNewswirePartnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networksGoodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery
3mo agoACON ACONWAclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026GlobeNewswire141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure
3mo agoACON ACONWAclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical PracticeGlobeNewswireAbstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablationEarly findings from real-world evidence study demonstrate immense
4mo agoACON ACONWAclarion Announces Texas Spine Care Center as New CLARITY SiteGlobeNewswireTexas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatmentCLARITY is a prospective, randomized clinical
5mo agoACON ACONWAclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClubGlobeNewswireBROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented
5mo agoACON ACONWAclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan PlatformGlobeNewswirePartnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating
5mo agoACON ACONWAclarion Rejects Echo Lake Capital's Unsolicited Acquisition ProposalGlobeNewswireBROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary
5mo agoACON ACONWAclarion Stockholders Approve All Proposals at 2026 Annual MeetingGlobeNewswireBROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary
5mo agoACON ACONWAclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationGlobeNewswireExpands availability of Nociscan in the greater Los Angeles area with leading neuroscience groupAdds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic
5mo agoACON ACONWAclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyGlobeNewswireAward-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back painNociscan's underlying MRS technology enabled measurement of intradiscal propionic acid to
5mo agoACON ACONWAclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited ProposalGlobeNewswireBROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented
6mo agoACON ACONWAclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate EnrollmentGlobeNewswire"Matching the right procedure to the right patient is what moves the field forward" Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early
6mo agoACON ACONWAclarion Announces Inducement Grant to New Commercial Director, Western U.S.GlobeNewswireBROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary
6mo agoACON ACONWAclarion Announces Second Commercial Agreement with Weill Cornell MedicineGlobeNewswireBROOMFIELD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary
6mo agoACON ACONWAclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical AdoptionGlobeNewswireTriple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflowsAdvancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4
6mo agoACON ACONWAclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanGlobeNewswireCommercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing demand for Nociscan,
6mo agoACON ACONWAclarion Announces $2.5 Million Stock Repurchase PlanGlobeNewswireBROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary
6mo agoACON ACONWAclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back PainGlobeNewswirePatent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross marginsExpands intellectual property portfolio to 64 issued and pending patents worldwide,
7mo agoACON ACONWAclarion Receives Pinnacle Award for AI InnovationGlobeNewswireRecognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion,
7mo agoACON ACONWAclarion Announces Agreement with Weill Cornell MedicineGlobeNewswireBROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary
7mo agoACON ACONWAclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician VideoGlobeNewswireVideo featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practiceNearly 100 Nociscans performed at The London Clinic, reflecting
9mo agoACON ACONWAclarion Publishes 2026 Shareholder Letter from the ChairmanGlobeNewswireCompany anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE)
9mo agoACON ACONWAclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence GenerationGlobeNewswireExpands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedureSupports
10mo agoACON ACONWAclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028GlobeNewswireBROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary
10mo agoACON ACONWAclarion Provides 2025 Update and 2026 Corporate OutlookGlobeNewswireQuarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025,
11mo agoACON ACONWAclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)GlobeNewswireFeatured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case studySpecial Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes over
11mo agoACON ACONWAclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.GlobeNewswireProven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine,
1y agoACON ACONWAclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market ExpansionGlobeNewswireMarks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market
1y agoACON ACONWAclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTHGlobeNewswireCompany previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion's breakthrough Nociscan solution for chronic low back pain BROOMFIELD,
1y agoACON ACONWAclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data CatalystGlobeNewswireDebt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with
1y agoACON ACONWAclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience ConferenceGlobeNewswirePanel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the
1y agoACON ACONWAclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTHGlobeNewswireBROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented
1y agoACON ACONWAclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value DriversGlobeNewswireBROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented
1y agoACON ACONWFirst Patients Enrolled at UHealth – University of Miami in Aclarion's Pivotal CLARITY TrialGlobeNewswireEnrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold
1y agoACON ACONWAclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming CatalystsGlobeNewswireNociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first
1y agoACON ACONWAclarion, Inc. Announces Adjournment of Annual Meeting of StockholdersGlobeNewswireMeeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology
1y agoACON ACONWFirst Patient Enrolled in Aclarion's Groundbreaking CLARITY TrialGlobeNewswireThe first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to
1y agoACON ACONWAclarion to Present NOCISCAN Technology at Leading Spine Innovation ForumGlobeNewswireBROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented
1y agoACON ACONWAclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial SiteGlobeNewswireUHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgeryCLARITY is a prospective, randomized clinical
1y agoACON ACONWAclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial SiteGlobeNewswireUSC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability
1y agoACON ACONWAclarion Announces Texas Back Institute as New CLARITY Trial SiteGlobeNewswireTexas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical
1y agoACON ACONWAclarion Welcomes Advocate Health as CLARITY Trial SiteGlobeNewswireAdvocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low
1y agoACON ACONWAclarion Announces Commercial Agreement with Spine Institute of LouisianaGlobeNewswireExpands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and
1y agoACON ACONWAclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025GlobeNewswireBROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented
1y agoACON ACONWAclarion Announces Publication of Seminal Nociscan Cost-Effectiveness AnalysisGlobeNewswireIndependent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative DiscographyConclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10%